Pharmacokinetics and Tolerability of Extended-Release Quetiapine Fumarate in Han Chinese Patients with Schizophrenia

被引:11
|
作者
Li, Qian [1 ]
Su, Yun Ai [1 ]
Liu, Yi [1 ]
Chen, Jing Xu [2 ]
Tan, Yun Long [2 ]
Yang, Fu De [2 ]
Si, Tian Mei [1 ]
机构
[1] Peking Univ, Dept Clin Psychopharmacol, Inst Mental Hlth, Key Lab Mental Hlth,Minist Hlth, Beijing 100191, Peoples R China
[2] Beijing Huilongguan Hosp, Ctr Psychiat Res, Beijing, Peoples R China
关键词
REPORTED SEDATION PROFILE; DOUBLE-BLIND; IMMEDIATE-RELEASE; PLASMA-CONCENTRATIONS; N-DESALKYLQUETIAPINE; BIPOLAR DISORDER; SEX-DIFFERENCES; HUMAN LIVER; EFFICACY; PLACEBO;
D O I
10.1007/s40262-013-0127-9
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Background and Objective The extended-release formulation of quetiapine (quetiapine XR), which was developed to provide more convenient once-daily administration, has been widely studied to characterize its pharmacokinetics in Caucasian populations but has rarely been studied in an Asia population. This study was conducted to evaluate the pharmacokinetics and tolerability of quetiapine XR administered as a single dose (300 mg) and multiple doses (300, 600, and 800 mg) in Han Chinese patients with schizophrenia. Methods This was a single-center, open-label, single-dose and multiple-dose randomized study. Among the 55 randomized subjects, a total of 40 female or male patients in 300 mg (n = 13), 600 mg (n = 13), or 800 mg (n = 14) groups completed the study of quetiapine fumarate XR. The treatment phase consisted of 5 consecutive days and was preceded by a 1- to 2-day titration period for the 600 and 800 mg groups. Pharmacokinetic parameters for both quetiapine and N-desalkyl quetiapine (norquetiapine) were determined. The tolerability evaluation included adverse events (AEs) noted by monitoring, physical examinations, vital signs, and clinical laboratory tests. Results N-desalkyl quetiapine was formed from quetiapine with an approximate metabolite to parent ratio of 0.5 across the three dose groups. The geometric mean elimination half-life (t (A1/2)) of both quetiapine and N-desalkyl quetiapine was consistent for the three dosing groups (approximately 7 h for quetiapine and approximately 18 h for N-desalkyl quetiapine). The geometric mean maximum plasma concentrations (C (max)) at steady state (C (max,ss)) of quetiapine for the three groups were 467, 740, and 1,126 ng/mL, respectively, and for N-desalkyl quetiapine were 138, 262, and 426 ng/mL, respectively. The values for the geometric mean area under the plasma concentration-time curve over a dosing interval at the steady-state (AUC(ss)) of quetiapine were 5,094, 7,685, and 13,237 ng center dot h/mL, respectively, and for N-desalkyl quetiapine were 2,284, 4,341, and 7,216 ng center dot h/mL, respectively. The apparent oral clearance (CL/F) of quetiapine at steady state appeared to be comparable across the three dose groups. The pharmacokinetics of quetiapine XR were dose-proportional across the dosage range employed. The most common AE was somnolence, but all of the reported AEs were mild. There were no serious AEs or other significant AEs. Conclusion Quetiapine fumarate XR has a dose-proportional pharmacokinetic profile at doses ranging from 300 to 800 mg once daily, and a slower time to reach C (max) and steady state after 3 days of sequential dosing. Therefore, it offers a simple and rapid dose-escalation option and more convenient once-daily administration. The three dosages of quetiapine fumarate XR were generally well-tolerated in this pharmacokinetic study of Han Chinese patients with schizophrenia.
引用
收藏
页码:455 / 465
页数:11
相关论文
共 50 条
  • [21] Efficacy and tolerability of once-daily extended release quetiapine fumarate (quetiapine XR) monotherapy in patients with generalised anxiety disorder
    Atkinson, S.
    Khan, A.
    Joyce, M.
    Eggens, I.
    Baldytcheva, I.
    Brecher, M.
    INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY, 2008, 11 : 277 - 277
  • [22] AN OPEN STUDY OF THE PHARMACOKINETICS AND THE TOLERABILITY OF RACLOPRIDE EXTENDED-RELEASE CAPSULES IN PSYCHIATRIC-PATIENTS
    MCEVOY, JP
    MOVINOSSWALD, G
    UPPFELDT, G
    WILLIAMS, T
    DUTCHER, S
    APPERSON, J
    PSYCHOPHARMACOLOGY, 1993, 112 (2-3) : 371 - 374
  • [23] Quetiapine Extended Release In Schizophrenia
    Baldwin, Claudine M.
    Scott, Lesley J.
    CNS DRUGS, 2009, 23 (03) : 261 - 269
  • [24] Population Pharmacokinetics, Safety and Tolerability of Extended-Release Bupropion and Its Three Metabolites in Chinese Healthy Volunteers
    Fan Zhang
    Yan Li
    Jingqiu Hu
    Jinhua Zhong
    Huafang Li
    European Journal of Drug Metabolism and Pharmacokinetics, 2019, 44 : 339 - 352
  • [25] Analysis of potentially predictive factors of efficacy of adjunct extended-release quetiapine fumarate in patients with major depressive disorder
    Bauer, Michael
    Thase, Michael E.
    Liu, Sherry
    Earley, Willie
    Eriksson, Hans
    JOURNAL OF PSYCHOPHARMACOLOGY, 2015, 29 (05) : 565 - 574
  • [26] Impact of once-daily extended-release quetiapine fumarate on hospitalization length in patients with acute bipolar mania
    Bonafede, Machaon
    Locklear, Julie C.
    Wahlqvist, Peter
    Fajutrao, Liberty
    Szamosi, Johan
    Pan, Katy
    Eriksson, Hans
    JOURNAL OF COMPARATIVE EFFECTIVENESS RESEARCH, 2015, 4 (01) : 51 - 59
  • [27] Population Pharmacokinetics, Safety and Tolerability of Extended-Release Bupropion and Its Three Metabolites in Chinese Healthy Volunteers
    Zhang, Fan
    Li, Yan
    Hu, Jingqiu
    Zhong, Jinhua
    Li, Huafang
    EUROPEAN JOURNAL OF DRUG METABOLISM AND PHARMACOKINETICS, 2019, 44 (03) : 339 - 352
  • [28] Switching from other antipsychotics to once-daily extended release quetiapine fumarate in patients with schizophrenia
    Ganesan, S.
    Agarnbaram, V.
    Randeree, F.
    Eggens, I.
    Huizar, K.
    Meulien, D.
    CURRENT MEDICAL RESEARCH AND OPINION, 2008, 24 (01) : 21 - 32
  • [29] Pharmacokinetic profiles of extended release quetiapine fumarate compared with quetiapine immediate release
    Figueroa, Carlos
    Brecher, Martin
    Hamer-Maansson, Jennifer E.
    Winter, Helen
    PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY, 2009, 33 (02): : 199 - 204
  • [30] Extended-release quetiapine fumarate (quetiapine XR) monotherapy and quetiapine XR or lithium as add-on to antidepressants in patients with treatment-resistant major depressive disorder
    Bauer, Michael
    Dell'Osso, Liliana
    Kasper, Siegfried
    Pitchot, William
    Vansvik, Eva Dencker
    Koehler, Juergen
    Jorgensen, Leif
    Montgomery, Stuart A.
    JOURNAL OF AFFECTIVE DISORDERS, 2013, 151 (01) : 209 - 219